SCHEDULE: PPF Entities Update Autolus Therapeutics Stake Filing

PPF IM Ltd. and related entities have filed an amendment to their Schedule 13D, confirming their beneficial ownership of approximately 5.6% of Autolus Therapeutics plc's shares following an internal reorganization.

Summary

• This filing is an amendment to a Schedule 13D for Autolus Therapeutics plc, concerning the beneficial ownership of ADSs and ordinary shares.
• The reporting persons are Renata Kellnerova, AMALAR HOLDING s.r.o., PPF Group a.s., and PPF IM Ltd.
• PPF IM Ltd. is the record owner of 14,782,275 Ordinary Shares, representing approximately 5.6% of the outstanding shares as of August 10, 2026.
• The shares were transferred to PPF IM Ltd. via an intercompany transfer as part of an internal reorganization of the PPF group, completed on August 27, 2026.
• This reorganization did not involve any change in ultimate beneficial ownership or control, and was not undertaken to influence the control of Autolus Therapeutics plc.
• A Power of Attorney has been granted to Lubomr Krl and Radomr Johanna to execute and file necessary SEC forms (3, 4, 5, 13D/G) on behalf of the undersigned.
• The reporting persons have entered into a Joint Filing Agreement dated August 27, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily administrative in nature, with no immediate positive or negative financial implications.

Positives

• The internal reorganization was completed efficiently on August 27, 2026.
• The reporting persons have established a clear framework for SEC filings through a Joint Filing Agreement and Power of Attorney.

Negatives

• No new capital was deployed for the share acquisition; it was an internal transfer.
• The filing does not provide any new financial performance data or strategic updates for Autolus Therapeutics plc.

Risks

• The filing does not explicitly mention any new risks associated with the ownership of Autolus Therapeutics plc shares.
• Potential future regulatory scrutiny related to beneficial ownership reporting, although this filing appears to be administrative.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Autolus Therapeutics plc's future performance or the reporting persons' future intentions beyond standard reporting requirements.

Management Comments

• The reporting persons have entered into a Joint Filing Agreement to jointly file this Schedule 13D.
• The undersigned acknowledges that the attorneys-in-fact are not assuming the undersigned's responsibilities to comply with Sections 13(d), 13(g), and 16 of the Exchange Act.

Industry Context

StockSavvy.ai notes that this filing is primarily administrative, related to ownership disclosures under Section 13(d) of the Exchange Act. It reflects a restructuring within the PPF Group rather than a new investment or divestment strategy concerning Autolus Therapeutics plc.

Related Party Transactions

• The Ordinary Shares were transferred by PPF Biotech B.V. to PPF IM Ltd. via an intercompany transfer as part of an internal reorganization of the PPF group of companies.

Stakeholder Impact

• Shareholders: No immediate impact as beneficial ownership has not changed, only the reporting structure within the PPF Group.
• Management of Autolus Therapeutics plc: No direct impact, as the filing is an ownership disclosure.
• Regulatory Bodies (SEC): Compliance with reporting requirements is maintained.

Next Steps

• The reporting persons will continue to comply with Section 13(d) and Section 16 of the Exchange Act.
• The Power of Attorney remains in effect until the undersigned is no longer required to file Forms 3, 4, 5, or reports on Schedule 13G or 13D.

Key Dates

Keywords

Schedule 13D, Beneficial Ownership, Autolus Therapeutics, PPF Group, Internal Reorganization, SEC Filing, ADSs, Ordinary Shares